$50.00
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), a sequence that occurs in human plasma. It is studied in cell culture and animal models of extracellular matrix turnover, including collagen synthesis and the expression of matrix proteins.
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide first identified in human plasma. In substance registries the complex is recorded as prezatide copper. It is not an approved medicine in Canada or the United States, and the material supplied here is a research chemical.
GHK and GHK-Cu have been studied in fibroblast and keratinocyte cultures and in animal models. Published endpoints include collagen, dermatan sulfate and chondroitin sulfate production, gene expression profiling, and the measurement of inflammatory and oxidative stress markers. These are laboratory observations and have not been established in controlled human trials.
Technical Specifications
Research Context
Pathways that have been examined in the published literature include:
These are observations in laboratory models and should not be read as describing effects in a person or an animal outside a controlled study.
Storage and Handling
Testing and Quality Control
Every batch of GHK-Cu is released against the following checks:
1. HPLC (high-performance liquid chromatography): to confirm a purity profile of ≥99.0%.
2. MS (mass spectrometry): to confirm the molecular weight and identity of the tripeptide.
3. Copper complex verification: to confirm the molar ratio of copper to peptide.
For laboratory research use only. Not for human or veterinary use.
Further reading